Imbruvica: Ph II PCYC-1129 data

Data from 42 evaluable patients with steroid-dependent or refractory chronic GvHD in the Phase II portion of the open-label, U.S. Phase Ib/II PCYC-1129 trial showed that once-daily 420 mg oral Imbruvi...